在肥胖膝关节骨关节炎患者的辅助治疗中使用甲福明
Amany Abd Elaal Aiad1, Sahar Mohamed El-Haggar2, Amal Mohamed El-Barbary3
1Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, 31527, Egypt. amany_43927_pg@pharm.tanta.edu.eg.
Inflammopharmacology
|June 13, 2024
概括
在肥胖膝关节骨关节炎患者中,甲福明显著降低了炎症和软骨退化. 这种辅助疗法也改善了疼痛,硬和身体功能,提供了一个有前途的治疗选择.
科学领域:
- 风湿病学和内分泌学.
- 药理学和治疗学 药理学和治疗学
背景情况:
- 肥胖是膝关节骨关节炎 (OA) 的重要危险因素,加剧炎症和软骨退化.
- 甲福明是一种抗糖尿病药物,具有抗炎和潜在的软骨保护性质,需要在OA管理中进行调查.
研究的目的:
- 评估甲福明作为辅助治疗在患有膝关节OA的肥胖患者中的疗效.
- 评估甲福明对炎症标志物和软骨退化的影响.
- 为了确定甲胺对膝关节OA的临床症状的影响.
主要方法:
- 一项随机,双盲,安慰剂控制的研究,涉及50名肥胖膝关节OA患者.
- 患者接受了甲福明 (每天两次500毫克) 或安慰剂,两者结合赛莱科克西布 (每天200毫克) 持续12周.
- 测量了COMP,CTX-1和IL-1β的血清水平,WOMAC得分评估了疼痛,硬度和功能.
主要成果:
- 与安慰剂组相比,甲福林组的血清中COMP,CTX-1和IL-1β水平显著降低 (p <0.05).
- 在甲胺组 (p < 0.0001) 观察到WOMAC总得分的显著改善,包括疼痛,硬度和身体功能.
结论:
- 甲福明在减轻肥胖膝关节OA患者的软骨退化和炎症方面表现出有益作用.
- 在这种患者群体中,辅助性甲福明治疗可以显著改善临床结果,包括疼痛和功能.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
170
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
170
Insulin: Dosing Regimen and Adverse Effects
165
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
165
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Obesity
451
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
451


